NCT04452643View on ClinicalTrials.gov

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

BACMUNE (MV130)

BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)

OTHER

Placebo

Placebo is a solution on sodium chloride at 0.9%

Trial Locations (3)

42070

Hospital General de Pachuca, Pachuca

Ciudad de México

Instituto Nacional de Enfermedades Respiratorias (INER), Mexico City

Unknown

Hospital de Ciudad Valles, San Luis Potosí City

Sponsors

Lead Sponsor

Inmunotek S.L.
All Listed Sponsors
lead

Inmunotek S.L.

INDUSTRY

NCT04452643 - Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel | Biotech Hunter | Biotech Hunter